Sun Drops Suggestion That Halol Reinspection Request May Be Close
Indian Facility Is One Of Key Three Impacting Firm’s Ability To Grow In US Generics
Sun Pharma discussed its Halol facility, generic Revlimid and the firm’s recent outright acquisition of Taro during its recent Q1 2025 financial earnings call.
